Courage is not the absence of fear, but rather the judgement that something else is more important than fear
MATWIN, a wholly owned subsidiary of UNICANCER group (gathering all the French Comprehensive Cancer Centers), is the most prestigious and one of the few European programmes dedicated to accelerating early innovation in oncology. Within a few years, this experimental program that was originally led by the Great South West Canceropole, managed to rally/mobilize an international network of industrial and academic partners committed to support innovation in the fight against cancer.
Every year, MATWIN offers outreach sessions, training, assessments, coaching and network to optimize oncology European research exposure and attractiveness on a global scale. A wide ecosystem (major pharmaceutical groups, biotechs, canceropoles, TTOs, competitive clusters, incubators, investors, etc.) is involved within MATWIN’s open innovation action.
FASTBASE Solutions, with its QF-Pro® technology, has been selected as a finalist for MATWIN 2020, after passing several in-depth evaluation milestones in a highly competitive contest, where different technologies aimed at fighting cancer have been assessed by a select International Board composed by prestigious international scientists and key decision makers from large pharmaceutical companies, such as Novartis, Gilead, Pzifer, BMS, Boheringer-Ingelheim, Merck, Roche, Pierre-Fabre or Sanofi, amongst others.
The recognition of a demanding program such as MATWIN is another important business milestone, that provides the company with a deserved notoriety and credibility and with privileged access to a network of key decision makers in corporations and venture capital, accelerating its strategic alliance-making potential. The project will be presented at the next MATWIN International Board on October 13th- 14th 2020 in Bordeaux France.